IDF 或修订版 NCEP ATP III 定义的代谢综合征与马来西亚 2 型糖尿病患者血糖控制的关系。,Diabetology & Metabolic Syndrome

当前位置： X-MOL 学术 › Diabetol. Metab. Syndr. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

IDF 或修订版 NCEP ATP III 定义的代谢综合征与马来西亚 2 型糖尿病患者血糖控制的关系。
Diabetology & Metabolic Syndrome ( IF 3.4 ) Pub Date : 2020-08-05 , DOI: 10.1186/s13098-020-00575-7
Riyadh Saif-Ali ₁ , Nor Azmi Kamaruddin ₂ , Molham Al-Habori ₁ , Sami A Al-Dubai ₃ , Wan Zurinah Wan Ngah ₄

Affiliation

随着代谢综合征 (MetS) 危险因素数量的增加，2 型糖尿病 (T2D) 的慢性并发症（例如大血管疾病）会加剧。本研究旨在研究国际糖尿病联盟 (IDF) 或修订后的国家胆固醇教育计划成人治疗小组 III (NCEP ATP III) 标准诊断的 MetS 与血糖控制、空腹血糖 (FBG)、糖化血红蛋白 (FBG) 的关系。 T2D 患者的 HbA1c)、C 肽和胰岛素抵抗。该研究是一项横断面观察性研究，涉及 485 名在马来西亚吉隆坡马来西亚国民大学医学中心 (UKMMC) 接受治疗的 T2D 患者。T2D 患者的 MetS 诊断基于 IDF 和修订后的 NCEP ATP III 标准。C肽和HbA1c水平分别通过自动定量免疫分析仪和高效液相色谱法测定。MetS 因素；通过分光光度计测量FBG、甘油三酯和高密度脂蛋白胆固醇。应用 IDF 和修订后的 NCEP ATP III 标准分别导致 73% 和 85% 的 T2D 受试者被诊断为 MetS。这些标准在 T2D 患者中诊断 MetS 的一致性较低（κ = 0.33，P < 0.001）。IDF 和修订后的 NCEP ATP III 标准均表明，具有 5 个 MetS 因素的 T2D 患者具有较高的胰岛素抵抗（P = 2.1 × 10−13；1.4 × 10−11）、C 肽（P = 1.21 × 10−13；4.1 × 10−11)、FBG (P = 0.01; 0.021) 和 HbA1c (P = 0.039; 0.018) 分别高于没有 MetS 的 T2D 患者。尽管 IDF 与修订后的 NCEP ATP III 标准在 T2D 患者 MetS 诊断方面的一致性较低，但这两个标准均显示，具有 5 个 MetS 因素的 T2D 患者具有较高的胰岛素抵抗、C 肽、FBG 和 HbA1c。

"点击查看英文标题和摘要"

Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes.

The chronic complications of Type 2 Diabetes (T2D) such as macrovascular disease is amplified with the increase in the number of metabolic syndrome (MetS) risk factors. This research aims to study the relationship of MetS, diagnosed by the International Diabetes Federation (IDF) or revised National Cholesterol Education Programs Adult Treatment Panel III (NCEP ATP III) criteria, with glycemic control, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), C-peptide, and insulin resistance in T2D patients. The study is a cross-sectional observational study which, involved 485 T2D patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. The MetS among the T2D patients was diagnosed based on IDF and revised NCEP ATP III criteria. C-peptide and HbA1c levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography, respectively. The MetS factors; FBG, triglyceride, and high-density lipoprotein cholesterol were measured by spectrophotometer. Application of the IDF and revised NCEP ATP III criteria respectively resulted in 73% and 85% of the T2D subjects being diagnosed with MetS. The concordance of these criteria in diagnosing MetS among T2D patients was low (κ = 0.33, P < 0.001). Both IDF and revised NCEP ATP III criteria indicated that T2D patients with 5 MetS factors had higher insulin resistance (P = 2.1 × 10−13; 1.4 × 10−11), C-peptide (P = 1.21 × 10−13; 4.1 × 10−11), FBG (P = 0.01; 0.021), and HbA1c (P = 0.039; 0.018) than those T2D patients without MetS, respectively. Although there is a low concordance between IDF and revised NCEP ATP III criteria in the diagnosis of MetS among T2D patients, both criteria showed that T2D patients with 5 MetS factors had higher insulin resistance, C-peptide, FBG, and HbA1c.

更新日期：2020-08-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南